Pepgen reports first quarter 2024 financial results and recent corporate highlights

– connect1-edo51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – freedom1-dm1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – n et proceeds of $86.3 million from common stock offerings extending cash runway into 2026 – boston, may 14, 2024 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended march 31, 2024. “our team has made exceptional progress in the first quarter advancing multiple clinical trials for duchenne muscular dystrophy (dmd) and myotonic dystrophy type 1 (dm1),” said james mcarthur, ph.d.
PEPG Ratings Summary
PEPG Quant Ranking